Özdöver Ali Caner, Gündeş İlknur, Kırık Melda Pelin, Haydaroğlu Şahin Handan, Sucu Murat, Pehlivan Mustafa
Gaziantep University Faculty of Medicine, Department of Internal Medicine, Gaziantep, Turkey
Gaziantep University Faculty of Medicine, Department of Hematology, Gaziantep, Turkey
Turk J Haematol. 2019 Feb 7;36(1):19-24. doi: 10.4274/tjh.galenos.2018.2018.0015. Epub 2018 Oct 24.
Hematopoietic stem cell transplantation (HSCT) is a choice of treatment for malignant and non-malignant diseases. After HSCT, some complications may develop in patients. Cardiac complications are particularly important. The aim of this study was to investigate whether systolic pulmonary artery pressure (PAP) is a marker for overall survival (OS) in HSCT patients.
In our study, 428 HSCT patients were evaluated. Ejection fraction (EF) and PAP values were investigated during symptom-oriented echocardiography in the pre-HSCT and post-HSCT periods.
Pre-HSCT EF values were similar between the groups. In patients with autologous HSCT (auto-HSCT) (PAP >25 mmHg), it was found that the 5-year mortality rate was 48.6%, while in the other group (PAP <25 mmHg) the 5-year mortality was 25.5%. There was a significant association between 5-year mortality rate and PAP level (p<0.046) in the auto-HSCT group. OS was 38% in the pre-auto-HSCT period with PAP values of >25 mmHg, while OS was 61% in the pre-auto-HSCT period with PAP values of <25 mmHg (p<0.001). We determined that there was a statistically significant difference between OS and PAP levels in patients with auto-HSCT. Five-year mortality rate and OS were not significantly different in patients undergoing allogeneic HSCT (allo-HSCT) (p>0.05).
Our results suggest that pre-HSCT PAP value is an important risk factor for mortality and OS in patients undergoing auto-HSCT.
造血干细胞移植(HSCT)是治疗恶性和非恶性疾病的一种选择。HSCT后,患者可能会出现一些并发症。心脏并发症尤为重要。本研究的目的是调查收缩期肺动脉压(PAP)是否是HSCT患者总生存期(OS)的一个标志物。
在我们的研究中,对428例HSCT患者进行了评估。在HSCT前和HSCT后的症状导向超声心动图检查期间,研究了射血分数(EF)和PAP值。
各组间HSCT前EF值相似。在自体HSCT(auto-HSCT)患者中(PAP>25 mmHg),发现5年死亡率为48.6%,而在另一组(PAP<25 mmHg)中,五年死亡率为25.5%。auto-HSCT组的5年死亡率与PAP水平之间存在显著关联(p<0.046)。auto-HSCT前PAP值>25 mmHg时,OS为38%,而auto-HSCT前PAP值<25 mmHg时,OS为61%(p<0.001)。我们确定auto-HSCT患者的OS和PAP水平之间存在统计学显著差异。接受异基因HSCT(allo-HSCT)的患者的5年死亡率和OS没有显著差异(p>0.05)。
我们的结果表明HSCT前PAP值是接受auto-HSCT患者死亡率和OS的一个重要危险因素。